ms EVA TEMKIN — Lobbyist Profile | Poliscope

ms EVA TEMKIN

Filings

Clients

Firms

Years active

2022–2022

Associated filing income

$20,000

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
BOEHRINGER INGELHEIM PHARMACEUTICALS INC	4	2022

Firm	Filings	Years
KING & SPALDING LLP	4	2022

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

Lowering Costs by Improving Biosimilar Uptake Act

Cited source text

H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act

Lowering Costs by Improving Biosimilar Uptake Act

Cited source text

H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

2022 · second_quarter · Q2

Firm income: $10,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

PHA

Pharmacy

H.R. 7047, Lowering Costs by Improving Biosimilar Uptake Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

2022 · first_quarter · Q1

Firm income: $10,000Client expense: —Open original LDA filing ↗